Tag: abecma market demand

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the abecma market grown in recent years?

In recent times, the abecma market size has seen a XX (HCAGR). Its growth is projected to increase from $XX million in 2024 to $XX million in 2025, with a compound annual growth rate (CAGR) of XX%. Factors such as the approval of abecma for relapsed/refractory multiple myeloma, the advances in car t-cell therapy, rising cases of multiple myeloma, its high effectiveness in treatment-resistant instances and burgeoning investments in research and development, have all contributed to its growth during the historical period.

How is the abecma market size expected to evolve during the forecast period?

In the coming years, the abcema market is projected to witness sustained growth with a forecasted compound annual growth rate (CAGR) of XX%. By 2029, the market value is expected to touch $XX million. This growth prediction can be ascribed to factors such as the widening prevalence of multiple myeloma, the growth of approved indications, advancements in personalized medicine, expansion of the global market, and reduction in overall costs through improved manufacturing processes. The forecast period also sees a growing trend towards adoption in initial lines of treatment, expansion of the geographic market, innovative developments in car t-cell therapy, the implementation of combination therapy strategies, customization and precision in medicine, and a heightened focus on relapsed/refractory multiple myeloma.

Get your abecma market report here!

https://www.thebusinessresearchcompany.com/report/abecma-global-market-report

Which key drivers are propelling the abecma market’s growth?

The prevalence of multiple myeloma is on the rise, a factor that is anticipated to accelerate the expansion of the abecma market. Multiple myeloma is a variety of blood cancer that influences plasma cells, a specific type of white blood cell that is located in bone marrow. The surge in multiple myeloma cases can be attributed to an aging demographic, betterment in diagnostic methods, and heightened awareness about the disease. Abecma is a CAR T-cell therapy that is efficacious in treating multiple myeloma. It employs genetically modified immune cells to pinpoint and eradicate cancerous plasma cells, granting a new alternative for patients who have relapsed or refractory forms of the ailment. For example, the American Cancer Society, a non-profit organization in the US committed to the obliteration of cancer, projected 35,780 myeloma cases in January 2024, which is an increase from the 34,470 cases reported in 2022. Hence, the surge in multiple myeloma prevalence propels the abecma market.

What are the market segments in the abecma industry?

The abecmamarket covered in this report is segmented –

1) By Indication: Multiple Myeloma; B-Cell Lymphoma (BCL); Acute Lymphoblastic Leukemia (ALL)

2) By End User: Adult; Geriatric

3) By Distribution Channel: Hospitals And clinics; Retail And Speciality Pharmacies; Online Pharmacies

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19847&type=smp

Which leading companies are shaping the growth of the abecma market?

Major companies operating in the abecma market include Bristol-Myers Squibb

What key trends are currently impacting the abecma market’s development?

The primary trend in the abecma market revolves around the creative treatments, including chimeric antigen receptor T cell therapy (CAR T), intended to improve patient results, target particular cancer strains more effectively, and increase the treatment choices for individuals with relapsed or refractory multiple myeloma. Chimeric antigen receptor T cell therapy (CAR T) is an advanced form of immunotherapy largely used to treat specific cancer types, such as leukemia and lymphoma, by genetically modifying a patient’s own T cells (a kind of white blood cell) to more effectively recognize and obliterate cancer cells. For example, Bristol Myers Squibb, a US-based pharmaceutical company, obtained the endorsement of the European Commission (EC) for Abecma (idecabtagene vicleucel; ide-cel), a CAR T-cell therapy engineered to treat adult patients with relapsed and refractory multiple myeloma in March 2024. This approval particularly aims at patients who have undergone at least two earlier treatments, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody, and who have shown disease progression following their last therapy.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19847

Which geographic areas are influencing the growth of the abecma market?

North America was the largest region in the abecma market in 2024. The regions covered in the abecma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Cell and Gene Therapy Manufacturing Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-manufacturing-services-global-market-report

Cell And Gene Therapy Supply Chain/Logistics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-supply-chain-or-logistics-global-market-report

Cell and Gene Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the abecma market grown in recent years?

In recent times, the abecma market size has seen a XX (HCAGR). Its growth is projected to increase from $XX million in 2024 to $XX million in 2025, with a compound annual growth rate (CAGR) of XX%. Factors such as the approval of abecma for relapsed/refractory multiple myeloma, the advances in car t-cell therapy, rising cases of multiple myeloma, its high effectiveness in treatment-resistant instances and burgeoning investments in research and development, have all contributed to its growth during the historical period.

How is the abecma market size expected to evolve during the forecast period?

In the coming years, the abcema market is projected to witness sustained growth with a forecasted compound annual growth rate (CAGR) of XX%. By 2029, the market value is expected to touch $XX million. This growth prediction can be ascribed to factors such as the widening prevalence of multiple myeloma, the growth of approved indications, advancements in personalized medicine, expansion of the global market, and reduction in overall costs through improved manufacturing processes. The forecast period also sees a growing trend towards adoption in initial lines of treatment, expansion of the geographic market, innovative developments in car t-cell therapy, the implementation of combination therapy strategies, customization and precision in medicine, and a heightened focus on relapsed/refractory multiple myeloma.

Get your abecma market report here!

https://www.thebusinessresearchcompany.com/report/abecma-global-market-report

Which key drivers are propelling the abecma market’s growth?

The prevalence of multiple myeloma is on the rise, a factor that is anticipated to accelerate the expansion of the abecma market. Multiple myeloma is a variety of blood cancer that influences plasma cells, a specific type of white blood cell that is located in bone marrow. The surge in multiple myeloma cases can be attributed to an aging demographic, betterment in diagnostic methods, and heightened awareness about the disease. Abecma is a CAR T-cell therapy that is efficacious in treating multiple myeloma. It employs genetically modified immune cells to pinpoint and eradicate cancerous plasma cells, granting a new alternative for patients who have relapsed or refractory forms of the ailment. For example, the American Cancer Society, a non-profit organization in the US committed to the obliteration of cancer, projected 35,780 myeloma cases in January 2024, which is an increase from the 34,470 cases reported in 2022. Hence, the surge in multiple myeloma prevalence propels the abecma market.

What are the market segments in the abecma industry?

The abecmamarket covered in this report is segmented –

1) By Indication: Multiple Myeloma; B-Cell Lymphoma (BCL); Acute Lymphoblastic Leukemia (ALL)

2) By End User: Adult; Geriatric

3) By Distribution Channel: Hospitals And clinics; Retail And Speciality Pharmacies; Online Pharmacies

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19847&type=smp

Which leading companies are shaping the growth of the abecma market?

Major companies operating in the abecma market include Bristol-Myers Squibb

What key trends are currently impacting the abecma market’s development?

The primary trend in the abecma market revolves around the creative treatments, including chimeric antigen receptor T cell therapy (CAR T), intended to improve patient results, target particular cancer strains more effectively, and increase the treatment choices for individuals with relapsed or refractory multiple myeloma. Chimeric antigen receptor T cell therapy (CAR T) is an advanced form of immunotherapy largely used to treat specific cancer types, such as leukemia and lymphoma, by genetically modifying a patient’s own T cells (a kind of white blood cell) to more effectively recognize and obliterate cancer cells. For example, Bristol Myers Squibb, a US-based pharmaceutical company, obtained the endorsement of the European Commission (EC) for Abecma (idecabtagene vicleucel; ide-cel), a CAR T-cell therapy engineered to treat adult patients with relapsed and refractory multiple myeloma in March 2024. This approval particularly aims at patients who have undergone at least two earlier treatments, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody, and who have shown disease progression following their last therapy.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19847

Which geographic areas are influencing the growth of the abecma market?

North America was the largest region in the abecma market in 2024. The regions covered in the abecma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Cell and Gene Therapy Manufacturing Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-manufacturing-services-global-market-report

Cell And Gene Therapy Supply Chain/Logistics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-supply-chain-or-logistics-global-market-report

Cell and Gene Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Projected Compound Annual Growth Rate (CAGR) of the Abecma Market from 2025 to 2034, and What Factors Influence It?

In recent times, the abecma market has experienced a XX (CAGR) growth. Projected growth is expected to rise from $XX million in 2024 to $XX million in 2025, showcasing a compound annual growth rate (CAGR) of XX%. The historical growth trend of the abecma market is linked to the approval of abecma for treating relapsed/refractory multiple myeloma, advancements in car t-cell therapy, an increased prevalence of multiple myeloma, high effectiveness in cases resistant to treatment, and the growth in research and development investments.

The market size for abcema is predicted to experience a constant annual growth rate (CAGR) of XX%, escalating to a valuation of $XX million in 2029. This anticipated surge over the forecast period is largely due to the increasing occurrence of multiple myeloma, an expansion in approved indications, and innovation in personalized medicine. Furthermore, aspects contributing to this forecast growth include worldwide market expansion, enhancements in manufacture and reduction in expenses. The forecast period is also expected to see significant trends such as expanded adoption in initial treatment stages, extension of the geographic market, technological breakthroughs in car t-cell therapy, and an increased focus on personalized and precision medicine. Additionally, addressing the ongoing issue of relapsed/refractory multiple myeloma is considered a key priority for the forecast period.

What Key Drivers Are Accelerating the Growth of the Abecma Market During the Forecast Period?

The increasing occurrence of multiple myeloma is anticipated to stimulate the expansion of the abecma market in the future. Multiple myeloma, a blood cancer, impacts plasma cells which are a subcategory of white blood cells present in the bone marrow. The heightened occurrence of multiple myeloma can be attributed to an aging populace, enhanced diagnostic methods, and heightened disease awareness. Abecma, classified as a CAR T-cell therapy, is beneficial in combating multiple myeloma. It does this by employing genetically altered immune cells to identify and annihilate cancerous plasma cells, offering a new alternative for patients with relapsed or refractory forms of the disease. For example, in January 2024, the American Cancer Society, a non-profit US-based organization committed to eradicating cancer, projected 35,780 myeloma cases compared to 34,470 in 2022. Thus, the increasing prevalence of multiple myeloma propels the abecma market forward.

Request Your Free Abecma Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=19847&type=smp

Who Are the Leading Players Fueling Growth in the Abecma Market?

Major companies operating in the abecma market include Bristol-Myers Squibb

What Are the Emerging Trends Shaping the Future of the Abecma Market?

The abecma market is seeing a significant trend towards the development of innovative treatments such as chimeric antigen receptor T cell therapy (CAR T) to improve patient results, better target specific cancers, and widen the range of treatments available for those with recurrent or resistant multiple myeloma. CAR T is a revolutionary immunotherapy majorly used to treat some cancers such as leukemia and lymphoma. It’s a procedure that genetically modifies a patient’s T cells (a type of white blood cell) to effectively identify and eliminate cancer cells. For example, Bristol Myers Squibb, a pharmaceutical firm from the US, got the green light from the European Commission (EC) for their CAR T-cell therapy called Abecma (idecabtagene vicleucel; ide-cel) specifically meant to treat adults with relapsed and resistant multiple myeloma in March 2024. This approval is targeted at patients who have been through at least two previous therapies, such as an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody, and whose disease has progressed since their last treatment.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/abecma-global-market-report

Which Key Segments Define the Structure of the Abecma Market and Their Growth Potential?

The abecmamarket covered in this report is segmented –

1) By Indication: Multiple Myeloma; B-Cell Lymphoma (BCL); Acute Lymphoblastic Leukemia (ALL)

2) By End User: Adult; Geriatric

3) By Distribution Channel: Hospitals And clinics; Retail And Speciality Pharmacies; Online Pharmacies

Which Regions Are Driving Growth in the Abecma Market?

North America was the largest region in the abecma market in 2024. The regions covered in the abecma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Defines the Scope of the Abecma Market?

Abecma (idecabtagene vicleucel) is a CAR T-cell therapy used to treat relapsed or refractory multiple myeloma by targeting and eliminating malignant plasma cells. It involves reprogramming a patient’s own immune cells (T cells) to target and kill cancer cells.

Browse Through More Similar Reports By The Business Research Company:

Cell and Gene Therapy Manufacturing Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-manufacturing-services-global-market-report

Cell And Gene Therapy Supply Chain/Logistics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-supply-chain-or-logistics-global-market-report

Cell and Gene Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: